Apo-Metformin en es it fr

Apo-Metformin Brand names, Apo-Metformin Analogs

Apo-Metformin Brand Names Mixture

  • No information avaliable

Apo-Metformin Chemical_Formula


Apo-Metformin RX_link


Apo-Metformin fda sheet

Apo-Metformin FDA

Apo-Metformin msds (material safety sheet)

Apo-Metformin MSDS

Apo-Metformin Synthesis Reference

No information avaliable

Apo-Metformin Molecular Weight

211.215 g/mol

Apo-Metformin Melting Point

300 oC

Apo-Metformin H2O Solubility

1000 mg/L

Apo-Metformin State


Apo-Metformin LogP


Apo-Metformin Dosage Forms

Liquid for injection; Tablets for oral use (125 mg, 250 mg, or 500 mg)

Apo-Metformin Indication

For use in the treatment of hypertension.

Apo-Metformin Pharmacology

Methyldopa is an aromatic-amino-acid decarboxylase inhibitor in animals and in man. Only methyldopa, the L-isomer of alpha-methyldopa, has the ability to inhibit dopa decarboxylase and to deplete animal tissues of norepinephrine. In man the antihypertensive activity appears to be due solely to the L-isomer. About twice the dose of the racemate (DL-alpha-methyldopa) is required for equal antihypertensive effect. Methyldopa has no direct effect on cardiac function and usually does not reduce glomerular filtration rate, renal blood flow, or filtration fraction. Cardiac output usually is maintained without cardiac acceleration. In some patients the heart rate is slowed. Normal or elevated plasma renin activity may decrease in the course of methyldopa therapy. Methyldopa reduces both supine and standing blood pressure. Methyldopa usually produces highly effective lowering of the supine pressure with infrequent symptomatic postural hypotension. Exercise hypotension and diurnal blood pressure variations rarely occur.

Apo-Metformin Absorption

Absorption from the gastrointestinal tract is variable but averages approximately 50%.

Apo-Metformin side effects and Toxicity

The oral LD50 of methyldopa is greater than 1.5 g/kg in both the mouse and the rat. Symptoms of overdose include bloating, constipation, diarrhea, dizziness, extreme drowsiness, gas, light-headedness, nausea, severely low blood pressure, slow heartbeat, vomiting, and weakness.

Apo-Metformin Patient Information

No information avaliable

Apo-Metformin Organisms Affected

Humans and other mammals